Crinetics Pharmaceuticals CRNX Business Segments — Expenses Related To Paltusotine
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept crnx:ExpensesRelatedToPaltusotine.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's business segments — expenses related to paltusotine.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's business segments — expenses related to paltusotine?
- Crinetics Pharmaceuticals (CRNX) reported business segments — expenses related to paltusotine of $11.87M in Q1 2026.
- How has Crinetics Pharmaceuticals's business segments — expenses related to paltusotine changed year-over-year?
- Crinetics Pharmaceuticals's business segments — expenses related to paltusotine decreased by 31.2% year-over-year, from $17.25M to $11.87M.
- What does business segments — expenses related to paltusotine mean?
- This metric tracks the specific research and development expenditures allocated to the clinical advancement of the Paltusotine program. It encompasses costs related to clinical trials, regulatory filings, and manufacturing development for this specific therapeutic candidate. Investors use this to gauge the capital intensity and progress of the company's lead pipeline assets.